SFJ Pharmaceuticals

SFJ Pharmaceuticals accelerates the global clinical development and regulatory approval of innovative therapies by providing risk-sharing capital, expertise, and operational resources. It partners with biopharma companies to co-develop late-stage assets—especially in oncology and rare diseases—using a unique financial model that shares both risk and reward. Notable collaborations include Eisai’s lenvatinib for thyroid cancer, Pfizer’s Mylotarg for AML, Pfizer’s inotuzumab for ALL, Pfizer’s dacomitinib for NSCLC, Apellis’ pegcetacoplan/Empaveli for PNH, Nektar Therapeutics’ bempegaldesleukin for oncology/immunology indications, Apellis’ APL2 in hematology indications, and PhaseBio’s PB2452 as a reversal agent.